Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity.

Tumor immune escape is a major obstacle in cancer immunotherapy, but the mechanisms involved remain poorly understood. We have previously developed an immune evasion tumor model using an in vivo immune selection strategy and revealed Akt-mediated immune resistance to antitumor immunity induced by various cancer immunotherapeutic agents. In the current study, we used microarray gene analysis to identify an Akt-activating candidate molecule overexpressed in immune-resistant tumors compared with parental tumors. X-linked lymphocyte-regulated protein pM1 (XLR) gene was the most upregulated in immune-resistant tumors compared with parental tumor cells. Furthermore, the retroviral transduction of XLR in parental tumor cells led to activation of Akt, resulting in upregulation of antiapoptotic proteins and the induction of immune resistance phenotype in parental tumor cells. In addition, we found that transduction of parental tumor cells with other homologous genes from the mouse XLR family, such as synaptonemal complex protein 3 (SCP3) and XLR-related, meiosis-regulated protein (XMR) and its human counterpart of SCP3 (hSCP3), also led to activation of Akt, resulting in the upregulation of antiapoptotic proteins and induction of immune resistance phenotype. Importantly, characterization of a panel of human cervical cancers revealed relatively higher expression levels of hSCP3 in human cervical cancer tissue compared with normal cervical tissue. Thus, our data indicate that ectopic expression of XLR and its homologues in tumor cells represents a potentially important mechanism for tumor immune evasion and serves as a promising molecular target for cancer immunotherapy.

[1]  Tae Woo Kim,et al.  Activation of Akt as a mechanism for tumor immune evasion. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  T. Franke,et al.  PI3K/Akt: getting it right matters , 2008, Oncogene.

[3]  Tae Woo Kim,et al.  A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. , 2008, International journal of pharmaceutics.

[4]  T. Wu.  The role of vascular cell adhesion molecule-1 in tumor immune evasion. , 2007, Cancer research.

[5]  E. Jaffee,et al.  Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. , 2007, Cancer research.

[6]  P. Tsichlis,et al.  Regulation of the Akt kinase by interacting proteins , 2005, Oncogene.

[7]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[8]  Andrew D. Hamilton,et al.  Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt , 2004, Cancer Research.

[9]  C M Kendziorski,et al.  On parametric empirical Bayes methods for comparing multiple groups using replicated gene expression profiles , 2003, Statistics in medicine.

[10]  T. Wu,et al.  Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. , 2003, Cancer research.

[11]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[12]  T. Wu,et al.  Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. , 2001, The Journal of clinical investigation.

[13]  T. Wu,et al.  Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. , 2001, Cancer research.

[14]  T. Wu,et al.  Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. , 2000, Cancer research.

[15]  S. Rosenberg,et al.  Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.

[16]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Heyting,et al.  The gene encoding a major component of the lateral elements of synaptonemal complexes of the rat is related to X-linked lymphocyte-regulated genes , 1994, Molecular and cellular biology.

[18]  H. Garchon,et al.  The meiosis‐specific Xmr gene product is homologous to the lymphocyte Xlr protein and is a component of the XY body. , 1994, The EMBO journal.

[19]  W. Paul,et al.  Sequence analysis and expression of an X-linked, lymphocyte-regulated gene family (XLR) , 1987, The Journal of experimental medicine.

[20]  Christina Kendziorski,et al.  On Differential Variability of Expression Ratios: Improving Statistical Inference about Gene Expression Changes from Microarray Data , 2001, J. Comput. Biol..

[21]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[22]  H. Garchon.  The Xlr (X-linked lymphocyte regulated) gene family (a candidate locus for an X-linked primary immune deficiency). , 1991, Immunodeficiency reviews.

[23]  Garchon Hj.  The Xlr (X-linked lymphocyte regulated) gene family (a candidate locus for an X-linked primary immune deficiency). , 1991 .